Hong Kong Financial Secretary Paul Chan Says City Ready to Be Biotech Bridge Connecting Global Capital with Chinese Innovation
Financial Secretary Paul Chan stated in an address to the Biotechnology Investment Forum of BIOHK2026 on Thursday that Hong Kong is poised to be the "partner of choice" for linking global capital with Chinese biotech innovation. Chan highlighted Hong Kong's position as the world's second-largest biotech fundraising platform, with nearly 300 healthcare companies listed on the Hong Kong Stock Exchange, boasting a combined market capitalization exceeding US$480 billion. He also noted that the Hong Kong Investment Corporation has allocated 22 percent of its funds to the biotech sector.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source:RTHK财经即时 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
U.S. Treasury Sanctions Chinese-Language Cyber-Scam Hub Xinbi Guarantee
-
2
24/7 Wall St. Initiates Marvell Technology (MRVL) with Buy Rating, Sets Price Target at $281.53
-
3
Understanding Cryptocurrency Mechanisms and a Buyer's Guide
-
4
MUNT Coin: Status and Market Analysis - Deconstructing an Inactive Crypto Project
-
5
What are the major global cryptocurrency trading platforms? An analysis of the current state of virtual currency regulation in mainland China.
-
6
KSE Coin: Disambiguating Projects and Trading Status
-
7
COCOS Token Upgraded to COMBO: Understanding How to Trade and Acquire the New Token
-
8
ENUT Token Status: Market Observation Under Extremely Low Liquidity
-
9
CTSC Coin: Current Value and Investment Analysis – A Delisted Token
-
10
UMY Coin: Current Status and Future Outlook – Distinguishing KaraStar UMY Token from Umy Travel Platform
Markets Today
Recommended Reading










